Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,806.00-0.15%ETH$2,282.82+0.63%GOLD$3,910.40+0.29%OIL$99.57-4.37%
Smart Investors Daily
SID Premium
OV

NASDAQ · OVID

Ovid Therapeutics Inc.

Healthcare · Biotechnology

$2.54

Down-$0.02 (-0.78%)

Updated Nov 2, 2026, 11:25 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
117.35M
P/E ratio
-0.06
Dividend yield
0.00%
52-week range
$1.18 – $3.11
Volume
3.15M
Avg. volume
2.89M

Price performance · OVID

OVID price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

OVID closed at $2.54 after 20 trading sessions, up 8.55% for the selected period.

Last close
$2.54
Period change
+8.55%
Period low
$2.15
Period high
$2.56
Daily close
View OHLC price history
OVID OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$2.51$2.70$2.44$2.543.15M
Oct 29, 2026$2.45$2.58$2.405$2.562.04M
Oct 28, 2026$2.26$2.495$2.205$2.452.06M
Oct 27, 2026$2.18$2.28$2.10$2.261.69M
Oct 26, 2026$2.19$2.22$2.1213$2.155844.07K
Oct 23, 2026$2.31$2.32$2.12$2.162.02M
Oct 22, 2026$2.45$2.50$2.34$2.371.18M
Oct 21, 2026$2.37$2.65$2.345$2.475.01M
Oct 20, 2026$2.19$2.46$2.175$2.363.67M
Oct 19, 2026$2.18$2.225$2.14$2.171.64M
Oct 16, 2026$2.26$2.30$2.11$2.151.33M
Oct 15, 2026$2.21$2.31$2.19$2.261.33M
Oct 14, 2026$2.18$2.255$2.09$2.191.64M
Oct 13, 2026$2.41$2.415$2.18$2.191.64M
Oct 12, 2026$2.45$2.4933$2.394$2.41876.04K
Oct 9, 2026$2.37$2.475$2.33$2.461.41M
Oct 8, 2026$2.32$2.36$2.29$2.341.65M
Oct 7, 2026$2.36$2.46$2.34$2.361M
Oct 6, 2026$2.42$2.44$2.27$2.371.74M
Oct 5, 2026$2.38$2.47$2.29$2.341.2M

Latest OVID news

The latest Smart Investors Daily articles mentioning OVID.

Stock researchCompany · Overview

OVID research

Overview

Company profile and research snapshot.

Company profile

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.50
Implied upside
—
Analysts
—
OVID recent ratings
DateFirmRatingTarget
Oct 15, 2026Wolfe ResearchOutperform—
Oct 9, 2026Cantor FitzgeraldOverweight—
Oct 6, 2026GuggenheimBuy—
Oct 5, 2026GuggenheimBuy—
Sep 11, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 15, 2026

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Matt David, M.D., as Chief Financial Officer. Dr. David will lead the Company's finance, accounting, capital markets and investor relations functions and will also serve as the Company's principal financial officer.

Yahoo · Oct 8, 2026

Ovid Therapeutics (OVID) Stock Gets Fair Value Boost As Analysts Focus On OV329

The latest fair value estimate for Ovid Therapeutics has shifted from US$5.47 to US$6.02 per share, keeping it within the current analyst price target range of US$5 to US$8. Research firms are linking this move to fresh discussion around OV329. More constructive views point to its clinical profile and the broader epilepsy pipeline, while cautious voices highlight execution risk and long timelines into 2026. As you read on, you will see how these moving parts shape the evolving analyst...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By